We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2676
Babcock & Wilcox
BW
$1.39B
| $376K | ﹤0.01% |
58,664
+2,062
| +4% | +$14.4K |
|
2677
Taysha Gene Therapies
TSHA
$1.89B
| $375K | ﹤0.01% |
20,131
+1,460
| +8% | +$27.8K |
|
2678
Erasca
ERAS
$6.39B
| $374K | ﹤0.01% |
+17,642
| New | +$364K |
|
2679
PureCycle Technologies
PCT
$1.45B
| $374K | ﹤0.01% |
28,154
+1,550
| +6% | +$23.4K |
|
2680
United States Lime & Minerals
USLM
$3.44B
| $370K | ﹤0.01% |
15,310
+485
| +3% | +$13.5K |
|
|
ARD
2681
DELISTED
Ardagh Group S.A. Class A Common Shares
ARD
| $370K | ﹤0.01% |
14,503
-1,354
| -9% | -$34K |
|
2682
MediaAlpha
MAX
$821M
| $367K | ﹤0.01% |
19,639
+1,180
| +6% | +$31.9K |
|
2683
Quantum Corp
QMCO
$474M
| $367K | ﹤0.01% |
3,547
+96
| +3% | +$11.3K |
|
2684
VirnetX Holding Corp
VHC
$63.1M
| $366K | ﹤0.01% |
4,665
+56
| +1% | +$4.58K |
|
2685
Lifecore Biomedical
LFCR
$190M
| $365K | ﹤0.01% |
39,589
+756
| +2% | +$8.23K |
|
2686
Vital Farms
VITL
$525M
| $365K | ﹤0.01% |
20,781
+1,150
| +6% | +$20.6K |
|
|
GPX
2687
DELISTED
GP Strategies Corp.
GPX
| $365K | ﹤0.01% |
17,609
-519
| -3% | -$10.3K |
|
2688
Atlanta Braves Holdings Series A
BATRA
$3.43B
| $363K | ﹤0.01% |
13,474
+155
| +1% | +$4.14K |
|
|
BFX
2689
DELISTED
BowFlex Inc.
BFX
| $363K | ﹤0.01% |
39,019
+1,300
| +3% | +$16.7K |
|
2690
Radiant Logistics
RLGT
$395M
| $362K | ﹤0.01% |
56,684
-31
| -0.1% | -$199 |
|
2691
Spero Therapeutics
SPRO
$73M
| $361K | ﹤0.01% |
19,590
+1,025
| +6% | +$16.4K |
|
|
BRT
2692
BRT Apartments
BRT
$271M
| $360K | ﹤0.01% |
18,652
+745
| +4% | +$13.8K |
|
2693
GCM Grosvenor
GCMG
$820M
| $358K | ﹤0.01% |
31,063
+2,870
| +10% | +$31.1K |
|
|
ICVX
2694
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $356K | ﹤0.01% |
+12,025
| New | +$408K |
|
|
RJET
2695
Republic Airways Holdings
RJET
$1B
| $355K | ﹤0.01% |
3,093
+79
| +3% | +$9.83K |
|
2696
iShares Russell Mid-Cap Growth ETF
IWP
$20.7B
| $352K | ﹤0.01% |
3,141
-2,165
| -41% | -$249K |
|
2697
Rekor Systems
REKR
$91.7M
| $350K | ﹤0.01% |
30,433
+1,448
| +5% | +$13.1K |
|
|
SURF
2698
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $350K | ﹤0.01% |
46,288
+1,850
| +4% | +$11.8K |
|
2699
Ares Capital
ARCC
$14.4B
| $349K | ﹤0.01% |
17,153
| – | – |
|
2700
Superior Group of Companies
SGC
$225M
| $349K | ﹤0.01% |
14,965
+363
| +2% | +$8.54K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.